B
Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.
Investor insights
Funding rounds participated in
$92M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology
Sectors
Biotechnology
Date founded
2020
Funding rounds raised
Total raised
$92M
from investors over 1 rounds
B
Be Biopharma raised $92M on February 15, 2025